Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Oncology Right
  3. Jaypirca (pirtobrutinib) tablets Right
  4. What should be monitored in patients when they are on Jaypirca™ (pirtobrutinib) treatment?
Search Jaypirca (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Jaypirca ™ (pirtobrutinib) tablets

50 mg,100 mg

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

What should be monitored in patients when they are on Jaypirca™ (pirtobrutinib) treatment?

Patients being treated with Jaypirca (pirtobrutinib) should be monitored for infections, hemorrhage, cytopenia, atrial fibrillation and atrial flutter, and the development of second primary malignancies.

US_cFAQ_PIR067_MONITORING
cFAQ
cFAQ
US_cFAQ_PIR067_MONITORING
en-US

Monitoring During Pirtobrutinib Treatment

Patients being treated with pirtobrutinib should be monitored for

  • infections
  • hemorrhage
  • cytopenia
  • atrial fibrillation and atrial flutter, and
  • the development of second primary malignancies.1

In the event of an adverse reaction, pirtobrutinib can be 

  • dose reduced
  • temporarily withheld, or
  • permanently discontinued.1

Infections

Patients treated with pirtobrutinib should be monitored for signs and symptoms of infections. The signs and symptoms should be evaluated and treated promptly as medically appropriate. Patients should be counseled to report any signs or symptoms of infection (eg, fever, chills, and weakness).1

Prophylaxis, including vaccinations and antimicrobial prophylaxis, should be considered for patients who are at an increased risk for infections, including opportunistic infections.1

Hemorrhage

Patients treated with pirtobrutinib should be monitored for signs of bleeding.1

The risks and benefits of withholding pirtobrutinib treatment for 3-7 days pre-surgery and post-surgery depending upon the type of surgery and risk of bleeding should be considered during treatment with pirtobrutinib. The benefit-risk should also be considered in the event of co-administration of antithrombotic agents with pirtobrutinib.1

Cytopenias

For patients treated with pirtobrutinib, complete blood counts should be monitored regularly during treatment.1

Atrial Fibrillation and Atrial Flutter

Patients treated with pirtobrutinib should be monitored for signs and symptoms of arrythmias (e.g., palpitations, dizziness, syncope, dyspnea) and managed appropriately. Patients should be counseled to report any signs of palpitations, dizziness, fainting, chest discomfort, and shortness of breath while on treatment.1

Second Primary Malignancies

Patients treated with pirtobrutinib should be monitored for the development of second primary malignancies. Patients should be counseled to use appropriate sun protection.1

Enclosed Prescribing Information

JAYPIRCA™ (pirtobrutinib) tablets, for oral use, Lilly

Reference

1Jaypirca [package insert]. Indianapolis, IN: Eli Lilly and Company; 2023.

Date of Last Review: December 16, 2022

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.17 02/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    facebook twitter linkedin
    visit www.phactmi.org
    Lilly